Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Straylighton Jun 29, 2021 1:01pm
148 Views
Post# 33466558

RE:RE:RE:Changeyoubet

RE:RE:RE:Changeyoubet True, its a consideration that I hadn't thought of before. Delaying P3 by a few months doesnt bother me too much (anything planned a year out is likely to experience some amount of delay, I dont consider a few months to be significant but it sounds like others do) but in general I view any delay as a bad thing.

There is a couple reasons they could be delayed and you add one that could be a positive:

Bad: Poor planning/scheduling, FDA is taking more time, other studies are taking longer, etc.
Good: If there is a serious partner or buyout opportunity and they want more control over P3, they may need more time to provide their input so it is run to their specifications. 

If there is a big partner or buyout opportunity that would also be a good reason to acceleate on the other fronts with the CRO. 

Who knows what the reality is, we will find out down the road of course.
<< Previous
Bullboard Posts
Next >>